Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo
Authors:
Open Access
- 1 April 2023
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 18, 2087-2107
Abstract
Purpose: The present study aimed to construct a co-loading platform encapsulating curcumin and paclitaxel at ratios of 2:1– 80:1 (w/w) designated “CU-PTX-LNP” and explored the synergistic effects of CU-PTX at different composite proportions on liver cancer cells using the combination index (CI) method. Methods: The CU lipid nanoplatform (CU-LNP) formulation was optimized via single-factor and orthogonal experiments. Various concentrations of PTX were added to the optimal formulation of CU-LNP to generate CU-PTX-LNP and the nanoplatform characterized via differential scanning calorimetry (DSC), transmission electron microscope (TEM), X-ray diffraction (XRD), zeta potential, polydispersity index (PDI), and size analyses. The cumulative release, stability, and cytotoxicity of CU-PTX-LNP in LO2, HepG2, and SMMC-7221 cells were assessed in vitro, followed by safety investigation and pharmacokinetic studies in vivo. The anti-tumor activity of CU-PTX-LNP was also evaluated using nude mice. Results: CU-PTX-LNP formulations containing CU:PTX at a range of proportions (2:1– 80:1; w/w) appeared as uniformly dispersed nanosized spherical particles with high entrapment efficiency (EE> 90%), sustained release and long-lasting stability. Data from in vitro cytotoxicity assays showed a decrease in the IC50 value of PTX of CU-PTX-LNP (by 5.47– 332.7 times in HepG2 and 4.29– 143.21 times in SMMC-7221 cells) compared to free PTX. In vivo, CU-PTX-LNP displayed excellent biosafety, significant anti-tumor benefits and enhanced pharmacokinetic behavior with longer mean residence time (MRT(0-t); CU: 4.31-fold, PTX: 4.61-fold) and half-life (t1/2z; CU: 1.83-fold, PTX: 2.28-fold) relative to free drugs. Conclusion: The newly designed CU-PTX-LNP platform may serve as a viable technological support system for the successful production of CU-PTX composite preparations.Keywords
This publication has 61 references indexed in Scilit:
- The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to CancerPharmacological Reviews, 2014
- Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical ModelAnnals of Biomedical Engineering, 2012
- PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacyInternational Journal of Pharmaceutics, 2011
- Multidimensional Atomic Force Microscopy: A Versatile Novel Technology for Nanopharmacology ResearchThe AAPS Journal, 2010
- Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicityThe Pharmacogenomics Journal, 2010
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- Bioavailability of Curcumin: Problems and PromisesMolecular Pharmaceutics, 2007
- Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerJournal of Clinical Oncology, 2005
- Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugsBiomaterials, 2005